New hope for stomach cancer: drug combo targets HER2-positive tumors
NCT ID NCT05671822
First seen Feb 17, 2026 · Last updated May 05, 2026 · Updated 10 times
Summary
This study tests a new drug called SHR-A1811 combined with chemotherapy and/or immunotherapy for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if the combination is safe and shrinks tumors. About 258 adults aged 18-75 who have not had prior treatment (or have failed standard therapy) are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 EXPRESSION GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital, FuDan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact
Conditions
Explore the condition pages connected to this study.